beta
AKTX
Akari Therapeutics Plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Market Cap: 39.5 Million
Primary Exchange: NASDAQ
Website: http://akaritx.com
Shares Outstanding: 21 Million
Float: 20.6 Million
Dividend: (%)
Beta: -0.0808321636727479
Sector: Health Technology
Industry: Pharmaceuticals: Major
Ethical Flags
Longest drawdown: 2014 trading days
From: 2014-01-15 To: 2020-01-22
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2015-09-17 | 10.0 | 1.0 | 10.0 |